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Summary Radioimmunoscintigraphy (RIS) can be used in the preoperative localisation of ovarian carcinoma
to demonstrate uptake of radiolabelled monoclonal antibodies into neoplastic tissue. The tissue uptake of
radiotracer was evaluated at laparotomy in 16 patients with suspected ovarian cancer who had preoperative
RIS using technetium-99m-labelled monoclonal antibodies SM3 and H17E2. A gamma detection probe ('DP)
was used to measure uptake in possible tumour deposits at operation and also the uptake in tissues resected
for histology. The percentage uptake of the initial injected dose of radiotracer was also measured in resected
tissues. Activity was found to be significantly higher in malignant than in non-neoplastic tissue by all three
methods of evaluation. The yDP used peroperatively yielded a 82% sensitivity with a 72% specificity for an
uptake ratio of 1.5:1. When tissue was examined immediately after resection, for a 100% specificity the
sensitivity was 64%. In vitro measurements of monoclonal antibody uptake by tissue similarly gave a 65%
sensitivity with a 100% specificity. Peroperative and immediate post-operative measurements of tissue radio-
activity can be performed quickly and conveniently, and in some cases may be of benefit in the localisation of
tumour at laparotomy and in providing extra information when tissue is examined by frozen section.
Ovarian cancer has the worst prognosis of all gynaecological
malignancies in the UK. It presents late and is often difficult
to differentiate from benign lesions until surgery and histo-
logical examination have been performed. The surgical man-
agement of ovarian carcinoma is more complex than that of
benign tumours and may be dictated by the results of histo-
logical frozen sections performed at the time of laparotomy.
This is especially important in young women with unilateral
ovarian tumours. In addition, a major factor determining the
prognosis is whether or not there has been complete resection
of the tumour. Therefore, accurate determination of the
amount and extent of the tumour is essential. CT scans,
pelvic ultrasound and surgical exploration, even when used
together, are less than 100% accurate (Lowe & Shepherd,
1991). However, radioimmunoscintigraphy using monoclonal
antibodies against polymorphic epithelial mucin and other
epitopes may yield more complete preoperative information
(Granowska et al., 1984, 1990, 1993; Davies et al., 1985;
Epenetos et al., 1985; Jackson et al., 1985; Critchley et al.,
1986; Shepherd et al., 1987; Jobling et al., 1990). We decided
to assess the value of peroperative radioimmunodetection
(PROD) using a specially designed gamma detection probe
(yDP). We have also studied the value of measuring mono-
clonal antibody uptake in excised tissue as an aid to inter-
preting a frozen section.
Patients and methods
Sixteen patients having conventional routine radioimmuno-
scintigraphy prior to surgery for proven or suspected ovarian
carcinoma were studied (Table I). All had a Karnofsky per-
formance status greater than 70%, a normal blood count and
electrolytes and liver function tests. They were all aged 40
years or older, and had given full written informed consent.
The study was approved by the City and Hackney Research
Ethics Committee and licensed by the Administration of
Radioactive Substances Advisory Committee of the Depart-
ment of Health and Social Services. The number of patients
recruited to the study was limited to 16 by the Research
Ethics Committee.
Patients were injected with technetium-99m (99Tcm)-labelled
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monoclonal antibody 24-30 h before surgery. This was fol-
lowed by conventional radioimmunoscintigraphy at 10min,
4-6 h and 20-24 h after injection. At laparotomy a gamma
detection probe (yDP) was used to evaluate possible sites of
tumour. The radioactivity in tissue specimens was measured
using an automated gamma counter.
Monoclonal antibodies
The monoclonal antibody SM3 reacts with an epitope on
polymorphic epithelial mucin (PEM) (Burchell et al., 1987);
the monoclonal antibody H17E2 reacts with an epitope of
placental and germ cell alkaline phosphatase (Travers &
Bodmer, 1984). The one patient who received H17E2 was
previously known to have a non-mucin-secreting granulosa
cell tumour. The antibodies were radiolabelled with 'Tcm
using the Mather and Ellison (1990) modification of the
Schwartz and Steinstrasser (1987) technique. The total
activity injected into each patient was 600 MBq bound to
0.5 mg of antibody. The immunoreactivity and in vitro and in
vivo stabilities of these 'Tcm monoclonal antibodies have
been reported previously by Mather and Ellison (1990).
Peroperative radioimmunodetection (PROD)
During surgery, a gamma detection probe (yDP) (C-Trak
Oncoprobe, Carewise, USA) was used to assess areas of
possible tumour involvement. The yDP consists of a cad-
mium telluride scintillation crystal, a preamplifier and an
amplifier with a digital readout. The probe was designed and
collimated for the 140 keV gamma ray energy of 99Tcm with a
20% window around the photopeak and had a linear re-
sponse up to 1,000 counts per second with a sensitivity of 22
counts per second per kilobequerel. The head of the probe
was angled for easier use at surgery and the scintillation
crystal was shielded and collimated so that most of the
radiation detected emerged from directly in front of the
probe.
The optimum threshold and window settings were estab-
lished using a 0.2 MBq source. After the abdominal cavity
was explored the yDP was used to assess the primary tumour
and other sites of possible involvement: Radioactivity that
might come from behind suspected lesions was shielded from
the probe using a 5 x 4 x 0.4 cm tungsten shield.
Counts were performed for 5 s and made in triplicate. For
each site identified by the probe, the mean counts of three 5 s
measurements in the lesion were expressed as a function of
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the mean counts in adjacent normal tissue (uptake ratio).
Activity values are expressed as a median for each group.
Results in malignant and non-malignant tissue were com-
pared using the Mann-Whitney U-test and presented with
95% confidence intervals of the difference between the group
medians.
Surgical specimens
Excised specimens were separated into areas of malignant
and non-neoplastic or benign tissue. Samples were weighed
and the radioactivity determined using an automated sample
counter. The values were corrected for decay since injection
and expressed as a percentage of the total injected dose per
gram of excised tissue.
Radioimmunoscintigraphy
Planar images were analysed by two nuclear physicians in the
absence of clinical information. Decisions were made as to
the likelihood of malignancy in any suspected lesion, together
with comments on general uptake by the liver, marrow,
vessels, kidney and colon. These were compared with the
surgical and histological findings.
Results
The results of radioimmunoscintigraphy are shown in Table
I.
In the 64 samples probed in vivo, the median uptake ratio
for histologically confirmed malignant sites was 4.2:1 com-
pared with 1.0:1 in non-affected sites (U = 820, P<0.001,
95% CI = 1.2-5.2). For specimens probed after resection,
the median uptake ratio in malignant tissue was 4.6:1 com-
pared with 2.3:1 in non-neoplastic (U = 27, P = 0.037, 95%
CI=0.2-11.1) (Figure 1).
In the 58 samples examined for tissue uptake of mono-
clonal antibody, the median percentage of the initial injected
dose per gram of tissue was 7.63 x 10-' % g-1 in malignant
tissue compared with 1.97 x 10' % g-' in non-neoplastic
tissue (U=528, P<0.0001, 95% CI=4.00X 10-3 to
6.71 x 10-3 % g-') (Figure 2).
The gamma detection probe used during operation had an
82% sensitivity for malignancy with a false-positive rate of
28% when an uptake ratio of 1.5:1 was used (Figure 3). An
uptake ratio of 2.3:1 yielded a 68% sensitivity for a 19%
false-positive rate (Figure 3). When used on resected speci-
mens the sensitivity with a zero false-positive rate was
64%.
Measurement of radiotracer uptake by tissue as a percent-
age of the injected dose per gram had a sensitivity of 81%
for malignancy with a 10% false-positive rate. The sensitivity
for a zero false-positive rate was 65% (Figure 3).
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Figure 1 Gamma detection probe results in vitro and after resec-
tion. The square boxes represent the median values.
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Figure 2 Comparison of tissue uptake of radiotracer between
non-malignant and malignant tissue. The square boxes represent
the median values.
Discussion
This study demonstrates that a gamma detection probe can
be used both per- and post-operatively to detect radiolabelled
antibodies bound to ovarian cancer cells. The results also
illustrate that detection is most efficient after the tissue is
resected either using the yDP or an automated gamma
counter. All three methods of detection may potentially be of
value in the per- and immediately post-operative detection of
Table I Patients and radioimmunoscintigraphy (RIS) results
Monoclonal Age
Case antibody (years) Diagnosis RIS
I SM3 59 Simple ovarian cyst Positive
2 SM3 51 Serous cystadenoma Equivocal
3 SM3 49 Benign cystic teratoma Positive
4 SM3 67 Mucinous cystadenoma Negative
5 SM3 78 Degenerated leiomyomata Negative
6 SM3 65 Borderline mucinous cystadenoma Positive
7 SM3 63 Stage la, mixed cystadenoma Positive
8 SM3 76 Stage la, grade 3, serous cystadenoma Positive
9 SM3 42 Stage Ic, grade 3, ovarian clear cell carcinoma Positive
10 Hi7E2 55 Stage 3, grade 3, ovarian granulosa cell tumour Positive
11 SM3 40 Stage 3, grade 3, serous cystadenocarcinoma Positive
12 SM3 48 Stage 3, grade 3, serous cystadenocarcinoma Positive
13 SM3 54 Stage 3, primary ovarian carcinoid tumour Positive
14 SM3 34 Stage 3, leiomyosarcoma Positive
15 SM3 72 Stage 3, grade 3, endometrial adenocarcinoma Positive
16 SM3 78 Ovarian metastasis of colonic adenocarcinoma Positive
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Figure 3 Receiver operator curve for the detection of malignant
spread in tissue. *, Tissue counts (per cent injected dose per
gram x 10-3); V, peroperative uptake ratio (malignant-non-
malignant).
ovarian cancer, however a larger study comparing this with
other methods of detection would be needed to confirm any
clinical worth.
Preoperative imaging by radioimmunoscintigraphy has
been shown to be of benefit using a variety of radionuclides
(Granowska et al., 1984, 1990; Davies et al., 1985; Epenetos
et al., 1985; Jackson et al., 1985; Critchley et al., 1986;
Shepherd et al., 1987; Jobling et al., 1990) but is still not part
of routine investigations for ovarian cancer in all specialist
centres. Granowska et al. (1993a), however, demonstrated
that 99Tcm-labelled anti-PEM monoclonal antibodies pro-
duced a 100% sensitivity with a 73% specificty for ovarian
cancer in external scanning. As a label, 99Tcm has the added
advantage of a short half-life (6 h), allowing a high activity
to be administered, giving a high count rate signal. Numer-
ous monoclonal antibodies have been used for radioimmuno-
detection, including those against PEM, placental alkaline
phosphatase and a number of other epitopes (Granowska et
al., 1984; Shepherd et al., 1987). Studies with flow cytometry
have shown that the monoclonal antibody SM3 has a higher
specificity for ovarian carcinoma than other antibodies (Van
Dam et al., 1991). This led Jobling et al. (1991) and Granow-
ska et al., 1990, 1993a) to use SM3-radiolabelled 99Tcm as the
first choice for radioimmunoscintigraphy.
The use of PROD in peroperative detection has been
explored in colorectal but not in ovarian cancer (Martin et
al., 1985; Granowska et al., 1991; Kuhn et al., 1991; Petty et
al., 1991; Waddington et al., 1991). Martin et al. (1985) first
demonstrated raised levels of activity in colorectal tumours
using iodine-125-labelled polyclonal antibody against car-
cinoembryonic antigen. Petty et al. (1991) correctly identified
the presence of tumour in 8 of 13 histologically confirmed
sites using an uptake ratio of 2:1 for the iodine-125-labelled
monoclonal antibody 17-lA. Granowska et al. (1993b) demon-
strated that, using an uptake ratio of greater than 1.5:1 with
99TcmNlabelled monoclonal antibody 1A3 correctly identified
17 of 19 histologically colorectal tumour sites.
In conclusion, the present study demonstrates that there is
strong binding of antibody SM3 in deposits of ovarian car-
cinoma. The gamma detection probe can be used in vivo or
after resection to measure the uptake of radiotracer quickly
and efficiently. With frozen section, by contrast, there is an
inevitable interval between resection and a histopathological
diagnosis, prolonging the time of anaesthesia. In addition, at
frozen section, the diagnosis of borderline and malignant
tumours affected by prior radiotherapy or infection can be
difficult. Histological examination should provide a definitive
diagnosis, but if the result is ambiguous the results of mono-
clonal antibody uptake in vivo or in vitro may help con-
siderably. In addition, since the test has a 65% sensitivity
with a zero false-positive rate for resected tissues, the surgeon
could make a positive decision without a histological diag-
nosis on 65% of occasions that tissue is excised for frozen
section. This could prevent subjecting patients with limited or
benign disease to the risks of radical surgery.
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